First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (NCT05277051)
A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- GSK Investigational Site — San Francisco, California
- GSK Investigational Site — Charlotte, North Carolina
- GSK Investigational Site — Oklahoma City, Oklahoma
- GSK Investigational Site — Philadelphia, Pennsylvania
- GSK Investigational Site — Dallas, Texas
- GSK Investigational Site — San Antonio, Texas
- GSK Investigational Site — Salt Lake City, Utah
- GSK Investigational Site — Nedlands, Western Australia
- GSK Investigational Site — Ottawa, Ontario
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Chengdu,
- GSK Investigational Site — Jinan,
- GSK Investigational Site — Shanghai,
- GSK Investigational Site — Wuhan,
- GSK Investigational Site — Dijon,
- GSK Investigational Site — Lille,
- GSK Investigational Site — Chiba,
- GSK Investigational Site — Tokyo,
- GSK Investigational Site — Seoul,
- GSK Investigational Site — Seoul,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Madrid,
- GSK Investigational Site — Madrid,
- GSK Investigational Site — Málaga,
- GSK Investigational Site — Manchester,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasms
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers — St Louis, Missouri
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) — Goodyear, Arizona
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors — Birmingham, Alabama
- Hispanic Adapted and Culturally Relevant Exercising Together — Tucson, Arizona
- M7824 Related Adverse Effects in Adults With Cancer — Bethesda, Maryland
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors — Duarte, California
Explore by condition: All Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.